TO THE EDITOR-We greatly appreciated the article of Scherrer et al [1] evaluating viral response to combination antiretroviral therapy (cART) in patients with subtype B (34.3% previously exposed to suboptimal therapies, P < .001) and nonsubtype B human immunodeficiency virus type 1 (HIV-1). The study brings to mind a similar article by Geretti et al [2] , but we found particularly reasonable the choice of Scherrer et al to restrict the analysis to a single ethnic group (whites), thus avoiding potential biases caused by ethnicity. The authors demonstrated that virological failure was higher in patients with subtype B; in particular, subtype A and CRF02_AG infections were associated with lower virological failure rates. Because certain non-B subtypes do not seem more susceptible to some drugs, why should these patients have a better response to cART? A lower propensity to select for nucleoside reverse-transcriptase inhibitor-and protease inhibitor-related mutations has been suggested for some non-B subtypes by Soares et al [3] .
It is our hypothesis that pretherapy differences might explain the improved response to cART in patients with non-B infection. For this purpose, we evaluated 168 (119 B and 49 non-B) newly diagnosed, Italian, antiretroviral-naive patients who had a follow-up of at least 6 months before starting cART. Subtype assignment (REGA-2 system, available at: http://jose.med.kuleuven.be/genotypetool/html/subtypinghiv.html) was performed by analyzing protease/reverse transcriptase/pol-integrase/env sequences coincident with the patients' first HIV-positive test. Outcomes considered were plasma viral load ( pVL; log 10 copies/mL) and CD4 slopes over time and initiation of cART (n = 59 subjects). Gender, age, hepatitis viruses coinfection, AIDS diagnosis, coreceptor tropism (geno2pheno, FPR:10%), and the presence of transmitted drug-resistance (TDR) mutations [4] were included in the analyses. Multivariate mixed models investigated the relationship between CD4 slope and pVL over time and subtype; models were adjusted for baseline values; interaction between subtype and time was added. Cox regression was used for univariate and multivariate models to assess risk factors for initiation of antiretroviral therapy.
Differences between antiretroviralnaive patients with B and non-B subtype are reported in Table 1 In conclusion, we found significant differences between non-B subtype and B subtype patients before cART initiation that might, at least in part, explain the improved virological outcomes reported by Scherrer et al [1] . Non-B subtype white patients entered into care earlier ( possibly because of an increased awareness of risky behavior), had no TDR (which increases the risk of virological failure after initiating treatment [5] ), and were significantly more likely to be infected with R5 viruses. This latter feature, which positively influences virological response to cART [6] , might have played an important role in the study of Scherrer et al. in which 60% of non-B strains were A, CRF02_AG, and C subtypes, and conceivably non syncytium-inducing (NSI)/R5 [7] [8] [9] .
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